Irbesartan/hydrochlorothiazide: In moderate to severe hypertension

Drugs

Volumn 68, Issue 10, 2008, Pages 1465-1472

  Croxtall, Jamie D ^a,b   Keating, Gillian M ^a,b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b WOLTERS KLUWER HEALTH   (United States)

Author keywords

Adis Drug Profiles; Hypertension; Irbesartan hydrochlorothiazide, general

Indexed keywords

AVALIDE; CYTOCHROME P450 INHIBITOR; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS IRBESARTAN; IRBESARTAN; NIFEDIPINE; SULFENAZOLE; TOLBUTAMIDE;

AREA UNDER THE CURVE; CLINICAL TRIAL; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; HEADACHE; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOKALEMIA; HYPOTENSION; KIDNEY CLEARANCE; MONOTHERAPY; PHARMACODYNAMICS; REVIEW; UNSPECIFIED SIDE EFFECT;

ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; CLINICAL TRIALS AS TOPIC; DRUG COMBINATIONS; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; SEVERITY OF ILLNESS INDEX; TETRAZOLES;

EID: 46249133520     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200868100-00007     Document Type: Review

References (19)

1. Mendis S, Lindholm LH, Mancia G, et al. World Health Organization (WHO) and International Society of Hypertension (ISH) risk prediction charts: assessment of cardiovascular risk for prevention and control of cardiovascular disease in low and middle-income countries. J Hypertens 2007 Aug; 25 (8): 1578-82
2. Hajjar I, Kotchen JM, Kotchen TA. Hypertension: trends in prevalence, incidence, and control. Annu Rev Public Health 2006; 27: 465-90
3. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007 Jun; 28 (12): 1462-536
4. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003 Dec; 42 (6): 1206-52
5. Staessen JA, O'Brien E. Will generic hypertension guidelines reduce the proliferation of directives? Heart 2007; 93: 775-7
6. Sanofi Aventis. Avalide (irbesartan-hydrochlorothiazide) tablets: US prescribing information [online]. Available from URL: http://www.sanofi-aventis. us [Accessed 2008 Mar 11]
7. Croom KF, Curran MP, Goa KL, et al. Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy. Drugs 2004; 64 (9): 999-1028
8. Saito F, Kimura G. Antihypertensive mechanism of diuretics based on pressure-natriuresis relationship. Hypertension 1996; 27: 914-8
9. Marino MR, Langenbacher KM, Ford NF, et al. Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of the angiotensin II blocker irbesartan. Clin Drug Invest 1997; 14 (5): 383-91
10. Marino MR, Lagenbacher K, Ford NF, et al. Pharmacokinetics and pharmacodynamics of irbesartan in healthy subjects. J Clin Pharmacol 1998; 38 (3): 246-55
11. Vachharajani NN, Shyu WC, Chando TJ, et al. Oral bioavailability and disposition characteristics of irbesartan, an angiotensin antagonist in healthy volunteers. J Clin Pharmacol 1998; 38 (8): 702-7
12. Patel RB, Patel UR, Rogge MC, et al. Bioavailability of hydrochlorothiazide from tablets and suspensions. J Pharm Sci 1984; 73 (3): 359-61
13. Beermann B, Groschinsky-Grind M. Pharmacokinetics of hydrochlorothiazide in man. Eur J Clin Pharmacol 1977 Dec 2; 12 (4): 297-303
14. Barbhaiya RH, Craig WA, Corrick-West HP, et al. Pharmacokinetics of hydrochlorothiazide in fasted and nonfasted subjects: a comparison of plasma level and urinary excretion methods. J Pharm Sci 1982; 71 (2): 245-8
15. Whittaker A. A review of olmesartan medoxomil: a new angiotensin II receptor blocker. Br J Cardiol 2005; 12: 125-9
16. Chando TJ, Everett DW, Kahle AD, et al. Biotransformation of irbesartan in man. Drug Metab Dispos 1998; 26 (5): 408-17
17. Bourrie M, Meunier V, Berger Y, et al. Role of cytochrome P-450 2C9 in irbesartan oxidation by human liver microsomes. Drug Metab Dispos 1999; 27 (2): 288-96
18. Neutel JM, Franklin SS, Lapuerta P, et al. A comparison of the efficacy and safety of irbesartan/HCTZ combination therapy with irbesartan and HCTZ monotherapy in the treatment of moderate hypertension. J Hum Hypertens 2008; 22 (11): 266-74
19. Neutel JM, Franklin SS, Oparil S, et al. Efficacy and safety of irbesartan/HCTZ combination therapy as initial treatment for rapid control of severe hypertension. J Clin Hypertens 2006; 8 (12): 850-7